(Q38157345)

29 August 2017

title

Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines (English)

1 reference

B-cell non-Hodgkin lymphoma

29 August 2017

1 reference

1 reference

6

Ranjana Advani

1 reference

29 August 2017

Daryl Tan

1

1 reference

29 August 2017

Soo Yong Tan

2

1 reference

29 August 2017

Soon Thye Lim

3

1 reference

29 August 2017

Seok Jin Kim

4

1 reference

29 August 2017

Won-Seog Kim

5

1 reference

29 August 2017

Yok-Lam Kwong

7

1 reference

29 August 2017

publication date

1 November 2013

1 reference

Lancet Oncology Commission

29 August 2017

published in

1 reference

29 August 2017

volume

14

1 reference

29 August 2017

issue

12

1 reference

29 August 2017

page(s)

e548-61

1 reference

Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

An update of the epidemiology of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Epidemiologic overview of malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Cancer trends and incidences in Singapore

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Double-hit B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Follicular lymphoma in Taiwan: a low frequency of t(14;18), with grade 3A tumours more closely related to grade 3B than to low-grade tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Translocation of bcl-2 gene in non-Hodgkin's lymphomas in Hong Kong Chinese

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Follicular lymphoma grade 3B.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Improved survival of follicular lymphoma patients in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Transformation of indolent B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Prognostic factors in follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Low-grade non-hodgkin lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma--role of radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

EBV-positive diffuse large B-cell lymphoma of the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

1 reference

7 January 2021

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial G

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Reg

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Nongastric marginal zone B-cell lymphoma: analysis of 247 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Initial immunoglobulin M ?flare? after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970450-9

7 January 2021

10.1016/S1470-2045(13)70450-9

Identifiers

DOI

1 reference

release_i53womafqjbgxjtid4wadtogs4

29 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/i53womafqjbgxjtid4wadtogs4

24 November 2022

mapped directly with Wikidata item

1 reference